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Pneumococcal carrierIn March 2010, Brazil introduced the 10-valent pneumococcal conjugate vaccine (PCV10) in the routine
infant immunization program using a 4-dose schedule and catch-up for children <23 months. We inves-
tigated PCV10 effect on nasopharyngeal carriage with vaccine-type Streptococcus pneumoniae (Spn) and
non-typeable Haemophilus influenzae (NTHi) among children in São Paulo city. Cross-sectional surveys
were conducted in 2010 (baseline) and 2013 (post-PCV10). Healthy PCV-naïve children aged
12–23 months were recruited from primary health centers during immunization campaigns.
Nasopharyngeal swabs were collected and tested for Hi; for Spn, all baseline and a stratified random sam-
ple of 400 post-PCV10 swabs were tested. We compared vaccine-type Spn and NTHi carriage prevalence
pre-/post-PCV10, and used logistic regression to estimate PCV10 effectiveness (1-adjusted odds
ratio  100%). Overall 501 children were included in the baseline and 1167 in the post-PCV10 survey
(including 400 tested for Spn). Spn was detected in 40.3% of children at baseline and 48.8% post-
PCV10; PCV10 serotypes were found in 19.8% and 1.8% respectively, representing a decline of 90.9%
(p < 0.0001). Carriage of vaccine-related serotypes increased (10.8–21.0%, p < 0.0001), driven primarily
by a rise in serotype 6C (1.8–11.2%, p < 0.0001); carriage of serotypes 6A and 19A did not significantly
change. PCV10 effectiveness (4 doses) against vaccine-type carriage was 97.3% (95% confidence interval
88.7–99.3). NTHi prevalence increased from 26.0% (130/501) to 43.6% (509/1167, p < 0.0001); PCV10 vac-
cination seemed significantly associated with NTHi carriage, even after adjusting for other known risk
factors. Carriage with PCV10 serotypes among toddlers declined dramatically following PCV10 introduc-
tion in São Paulo, Brazil. No protection of PCV10 against NTHi was observed. Our findings contribute to a
growing body of evidence of PCV10 impact on vaccine-type carriage and highlight the importance of
PCV10 as a tool to reduce the burden of pneumococcal disease in Brazil and globally.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).sp.gov.br
ail.com
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Streptococcus pneumoniae (Spn) and Haemophilus influenzae (Hi)
are important causes of morbidity and mortality worldwide, par-
ticularly among young children [1,2]. For each of these organisms,
colonization of the nasopharynx is a prerequisite for development
of disease, and serves as reservoir for spread [3,4]. Assessments of
the prevalence of nasopharyngeal carriage before and after vaccine
introduction can be used to evaluate vaccine impact [5]. Changes in
carriage following vaccine introduction provide important insight
into vaccine impact on invasive disease [6].
Routine use of the Haemophilus influenzae type b (Hib) conju-
gate vaccine has led to dramatic declines in Hib disease and colo-
nization [4]. However non Hi type b serotypes continue to
colonize children and can lead to invasive disease [7]. Non-
typeable Hi is also frequently found in the nasopharynx [8], and
is an important cause of pneumonia, otitis media, sinusitis, con-
junctivitis and bacteremia [9,10]. Pneumococcal conjugate vacci-
nes (PCVs) are highly effective against invasive disease and
nasopharyngeal colonization caused by pneumococcal vaccine ser-
otypes [11–13] resulting in both direct protection among vacci-
nated persons as well as herd protection resulting from reduced
transmission of vaccine serotypes [14]. However, much of those
data are from high-income settings and based on experience with
the 7-valent PCV (PCV7). Less is known about PCV impact in low-
and middle-income settings and the performance of the newer,
high-valent PCVs.
In 2010, Brazil become the first country to introduce the
10-valent PCV (PCV10) nationwide as a routine infant immuniza-
tion, using a schedule of 3 primary doses (at 2, 4, 6 months of
age) plus a booster dose (at 12–18 months) [15]. A catch-up cam-
paign was carried out, which offered 2 primary doses plus a boos-
ter for children aged 7–11 months, and a single dose for children
aged 12–23 months at the time of introduction [15]. PCV10 con-
tains serotypes 1, 5, 4, 6B, 7F, 9V, 14, 18C, 19F, and 23F. Eight of
the serotypes are conjugated to the non-typeable Hi (NTHi) protein
D; it has been suggested that PCV10 could reduce otitis media and
carriage by NTHi [16,17].
We investigated the effect of PCV10 introduction on nasopha-
ryngeal colonization with pneumococcal vaccine serotypes and
NTHi among healthy children living in the biggest metropolitan
area in Brazil and explored factors associated with colonization
in this context.2. Materials and methods
2.1. Study area and population
This study comprised two cross-sectional carriage surveys
among healthy children aged 12 up to 23 months residing in the
municipality of São Paulo. São Paulo is the largest metropolitan
region in Brazil, with a population of 11,253,503 inhabitants in
2010, including 710,929 children up to 5 years old [18]. The base-
line survey was performed in 2010, and the post-PCV10 survey was
conducted in 2013. The participants for both surveys were
recruited among children presenting to public Primary Health
Units (PHUs) during immunization campaigns carried out on three
different dates in 2010 (March 22, June 12 and August 14) and in
one in 2013 (June 6).
Children with fever, acute illness or reported antibiotic used
during the preceding week were excluded. Only one child per
household was enrolled. Children enrolled in the baseline survey
were required to have received 3 doses of Hib vaccine (since an
objective of that survey was to assess Hib vaccine impact). Some
participants in the 2010 survey had received doses of PCV10(which had been recently introduced) or 23-valent pneumococcal
polysaccharide vaccine (used for children with certain chronic dis-
eases) at the time of sample collection; however only those who
had not received any pneumococcal vaccine were included in the
baseline for this study of PCV10 impact. For the post-PCV10 survey,
prior receipt of Hib vaccine or PCV10 were not required and chil-
dren who had received a pneumococcal vaccine other than
PCV10 (i.e. 7-valent PCV or the polysaccharide vaccine) were
excluded.2.2. Sampling and sample size
For the baseline survey, recruitment was conducted at 14 PHUs
distributed across the five regions of the metropolitan area (North,
n = 2, Central-East, n = 5, East, n = 2, Southeast, n = 5, South, n = 3).
For the post-PCV10 survey, children were recruited from the same
14 PHUs as well as 10 additional PHUs (North, n = 4, Central-East,
n = 6, East, n = 3, Southeast, n = 6, South, n = 5) in order to enroll
the targeted number of children in a single day. The baseline sur-
vey included 501 children who had received no pneumococcal vac-
cination. (A total of 395 children enrolled at baseline had received
at least one dose of pneumococcal vaccine and were therefore
excluded from this study.) For the post-PCV10 sample size, we took
into account the baseline prevalence of carriage with PCV10 sero-
types (19.8%) and NTHi (26.0%) among those 501 children. Estimat-
ing a reduction of 40% in PCV10-serotypes and 20% of NTHi after
PCV10 introduction, we aimed to enroll at least 1320 children for
NTHi testing and planned to select 400 of those for testing for
Spn. We used a stratified random sample to ensure that the geo-
graphic distribution (North, Central-East, East, Southeast, and
South) of participants tested for Spn would be the same in the
post-PCV10 round as that of the baseline.2.3. Ethical considerations
The Ethics Committee of the Faculty of Public Health from
University of São Paulo (protocol #1969) and the Ethics Committee
of Adolfo Lutz Institute (protocol #229.877) approved the surveys
carried out in 2010 and 2013, respectively. The protocol for the
post-PCV10 survey was reviewed by the Centers for Disease Con-
trol and Prevention and determined to be program evaluation
and not human subjects research. In both surveys, parent(s)/
guardian(s) of participants provided written informed consent
before children were enrolled.2.4. Data and specimen collection
For both surveys, demographic and epidemiologic data were
gathered through a standardized questionnaire administered to
the parent/legal guardian of participating children before the
collection of nasopharyngeal specimens. Vaccination status for
PCV10 and Hib was assessed by reviewing the child’s immuniza-
tion card. Doses received at least 14 days before sample collection
were counted in the analysis.
In both surveys, a single transnasal nasopharyngeal swab sam-
ple per child was obtained by trained nurses using a flexible sterile
swab (FLOQ Swabs, Copan) according to WHO working group stan-
dard methods [19]. Swabs specimens were immediately inoculated
into 1.0 mL skim milk-tryptone-glucose-glycerol transport med-
ium (STGG) [20] and placed in a cold-box and delivered to Center
of Bacteriology at Adolfo Lutz Institute (IAL) within 4–5 h after
collection.
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At IAL, inoculated STGG vials were vigorously vortexed for
20–30 s and then stored at 70 C. For Spn culture, frozen vials
were thawed at room temperature and then vortexed for
20–30 s; 120 lL aliquots were inoculated into 3 mL of TYS broth
(Todd-Hewitt broth with 0.5% yeast extract and 600 lL of rabbit
serum) for enrichment culture [21]. Spn was identified by standard
methods [22] and was serotyped by Quellung reactions with antis-
era from Statens Serum Institute (Copenhagen, Denmark). All non-
typeable pneumococcal isolates by Quellung were confirmed by
conventional 8 PCR- multiplex comprising 70 serotypes [21,23].
Penicillin susceptibility was performed by screening for suscepti-
bility to oxacillin by disk diffusion (OXOID, Basingstoke, England),
following the CLSI procedure [24]. Spn with diminished suscepti-
bility to penicillin (Oxa halo 6 19 mm) were analyzed for mini-
mum inhibitory concentration (MIC) to penicillin and ceftriaxone
by Etest method (bioMerieux, USA) on 5% sheep-blood Muller Hin-
ton agar plate; MIC thresholds conferring resistance to penicillin
and to ceftriaxone were considered 60.06 mg/L and 61.0 mg/L,
respectively. MIC90 and MIC50 to penicillin were defined as the
MIC value of penicillin at which growth for 90% and 50% of the iso-
lates, respectively, was inhibited.
For Hi culture, 70 lL of inoculated STGG was plated in 10%
chocolate agar supplemented with 300 mg/L bacitracin. A sus-
pected colony of Haemophilus spp. on chocolate-agar plate was
submitted to standard procedures as oxidase test and V (NAD,
OXOID) and X (hemin, OXOID) factor requirements to Hi identifica-
tion [22]. All Hi isolates were confirmed by hpd#3 real time PCR
(qPCR) assay [25], and were typed by bexA [26] and by specific cap-
sule conventional PCR assays [27].
2.6. Data analysis
The primary outcomes were colonization with PCV10 serotypes
(1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F) and colonization with
NTHi. Children with more than one pneumococcal serotype
detected were classified as being colonized with a vaccine serotype
as long as one of the serotypes was vaccine-type. We also exam-
ined changes in the prevalence of PCV10-related serotypes, defined
as serotypes belonging to the same serogroup as a vaccine serotype
(i.e. 6A, 6C, 7C, 9N, 18A, 18B, 19A, 23A, and 23B) and non-PCV10
serotypes (excludes vaccine-related and non-typeable isolates).
Spn with negative reactions by Quellung and PCR for serotyping
were classified as non-typeable Spn (NT Spn). Prevalence in the
baseline and post-PCV rounds were compared using chi-square
test and medians compared using Wilcoxon rank sum test;
p < 0.05 was considered significant. We used logistic regression
models to estimate the effectiveness of PCV10 vaccination against
vaccine-type pneumococcal colonization and NTHi colonization
and to identify risk factors for colonization. Covariates with a
p-value < 0.2 on univariate analysis were assessed for potential
inclusion in the multivariate models; stepwise automated
selection was used to determine which variables remained in the
final adjusted models. Vaccine effectiveness was calculated as
1-adjusted odds ratio (aOR)  100% for PCV10 vaccination. Data
analysis was conducted using SAS statistical software (v.9.3).
3. Results
A total of 501 eligible children were included in the baseline
(including 477, 8 and 16 enrolled in March, June and August
respectively), and 1167 were enrolled in the post-PCV10 survey,
of which 400 were selected for Spn testing. The baseline andpost-PCV10 participants were similar with respect to age, sex,
and number of children aged 0–10 years residing in the household
(Table 1). Day care attendance and having P3 people sleep in the
same room as the child were significantly less common among
baseline participants; low maternal education, reporting a smoker
in the household, and having P3 persons aged P11 years in the
household were significantly more common among baseline
participants compared with the post-PCV10 survey population.
The geographic distribution of study participants differed between
the baseline and the overall post-PCV10 group, however those
selected for Spn testing were similar to baseline. In the post-
PCV10 survey, 95.0% of participants had received 3 or 4 doses of
PCV10.
Among 501 children in the baseline, 40.3% were colonized
with Spn (Table 1), including 5 children with 2 serotypes identi-
fied. Among 400 children tested for Spn in the post-PCV10 sur-
vey, 48.8% were colonized with Spn (p = 0.0113 compared with
baseline), including 3 children with 2 serotypes. A total of 33
pneumococcal serotypes were identified among 207 isolates in
the baseline survey and 29 serotypes among 198 isolates in the
post-PCV10 survey (Fig. 1). Among all isolates at baseline, the
most prevalent serotypes were 6B (n = 30, 14.5%), 19F (n = 27,
13.0%), 6A (n = 21, 10.1%), 14 (n = 20, 9.6%), and 23F (n = 16,
7.7%). Post-PCV10 the most common serotypes were 6C (n = 45,
22.7%), 6A (n = 16, 8.1%), and 11A (n = 14, 7.1%). PCV10 serotypes
were detected in 19.8% of children in the baseline (Table 1),
while the prevalence in the post-PCV10 survey was 1.8%, repre-
senting a decline of 90.9% (p < 0.0001). The prevalence of carriage
of non-PCV10 serotypes increased significantly from baseline to
the post-PCV10 survey (8.2% vs. 23.5%, p < 0.0001), as did
PCV10-related serotypes (10.8% vs. 21.0%, p < 0.0001), driven pri-
marily by an increase in serotype 6C (1.8% vs. 11.2%, p < 0.001).
There was no significant change in the prevalence of carriage of
6A or 19A.
Among 207 pneumococcal isolates from the baseline, 51.7%
(n = 107) had a MIC to penicillin > 0.06 mg/L, and 64.5% (n = 69)
of those belonged to PCV10-serotypes (serotypes 6B, 14, 19F and
23F); MIC90 and MIC50 to penicillin among the pre-PCV10 isolates
were 2.00 mg/L and 0.12 mg/L, respectively. Among 198 isolates
from the post-PCV10 survey, 40.4% (n = 80) had MIC to peni-
cillin > 0.06 mg/L, and 7.5% (n = 6) of those were vaccine-
serotype; MIC90 and MIC50 to penicillin decreased to 1.00 mg/L
and 0.06 mg/L, respectively. Only two isolates from the baseline
(serotype 23F and non-typeable) and one isolate from the post-
PCV10 survey (serotype 6A) had MIC = 2.0 mg/L for ceftriaxone.
The adjusted effectiveness for three and four doses of PCV10
against carriage by PCV10-serotypes was 92.7% (95% confidence
interval [CI] 79.6–97.4) and 97.3% (95% CI 88.7–99.3), respectively
(Table 2). Additional factors associated with colonization with
PCV10 serotypes were daycare attendance and concurrent colo-
nization with Hi.
Hi was identified in 27.7% of 501 children at baseline and 44.9%
of 1167 children in the post-PCV group (Table 1), representing an
increase of 62.1% (p < 0.0001). The majority of Hi isolates from both
the baseline (130/139, 93.5%) and the post-PCV round (509/524,
97.1%) were non-typeable. NTHi carriage increased from 26.0% to
43.6% (p < 0.0001). PCV10 vaccination was significantly more com-
mon among those colonized with NTHi compared with those not
colonized, resulting in a negative adjusted effectiveness (Table 3).
Daycare attendance was strongly associated with NTHi coloniza-
tion (aOR 7.270, 95% CI 5.619–9.405). Additional associated factors
included presence of a smoker in the household, low household
income, and P2 children aged 0–10 in the house in addition to
the study participant.
Table 1
Characteristics, vaccination status and nasopharyngeal colonization among children at baseline and post-PCV10 introduction in São Paulo, Brazil.a
Baseline
n = 501
Post-PCV10
n = 1167
Post-PCV10 subset tested for
Streptococcus pneumoniae
n = 400
n (%) n (%) p valueb n (%) p valuec
Characteristics
Median age in months (IQ Range) 17.0 (6.0) 17.0 (6.0) 0.5471 17.0 (6.0) 0.6563
Male sex 280 (55.9) 589 (50.5) 0.0423 203 (50.8) 0.1244
Attends day care 117 (23.4) 363 (31.1) 0.0013 126 (31.5) 0.0062
Mother educational level 6 8th grade 167 (33.9) 293 (25.3) 0.0003 97 (24.3) 0.0017
Smoker in the household 156 (31.2) 299 (25.6) 0.0191 107 (26.8) 0.1611
Household income 6 1530 R$ per month 272 (64.2) 843 (74.6) <0.0001 272 (70.6) 0.0492
P2 people aged 0–10 years in household d 192 (38.3) 498 (42.7) 0.0982 167 (41.8) 0.2966
P3 people aged P11 years in household 214 (42.7) 438 (37.5) 0.0468 145 (36.2) 0.0489
P3 people sleep in same room as child 111 (22.2) 329 (28.2) 0.0114 113 (28.3) 0.0365
Region
North 189 (37.7) 271 (23.2) <0.0001 151 (37.8) 0.9996
South 50 (10.0) 248 (21.2) 39 (9.8)
East 3 (0.6) 136 (11.6) 2 (0.5)
Central West 199 (39.7) 269 (23.0) 160 (40.0)
South East 60 (12.0) 243 (20.8) 48 (12.0)
Vaccination
Haemophilus influenzae type b vaccine
0 doses 0 (0) 29 (2.5) <0.0001 8 (2.0) <0.0001
1 dose 0 (0) 7 (0.6) 3 (0.8)
2 doses 0 (0) 38 (3.3) 9 (2.2)
3 doses 501 (100.0) 1093 (93.7) 380 (95.0)
PCV10
0 doses 501 (100.0) 0 (0) <0.0001 0 (0) <0.0001
1 dose 0 (0) 8 (0.7) 6 (1.5)
2 doses 0 (0) 50 (4.3) 22 (5.5)
3 doses 0 (0) 488 (41.8) 172 (43.0)
4 doses 0 (0) 621 (53.2) 200 (50.0)
Colonization
S. pneumoniae – any serotype 202 (40.3) – – 195 (48.8) 0.0113
PCV10 serotype 99 (19.8) – – 7 (1.8) <0.0001
PCV10-related serotype 54 (10.8) – – 84 (21.0) <0.0001
Serotype 6A 21 (4.2) 16 (4.0) 0.8855
Serotype 6C 9 (1.8) 45 (11.2) <0.0001
Serotype 19A 9 (1.8) – – 10 (5.1) 0.4562
Non-PCV10 serotypee 41 (8.2) – – 94 (23.5) <0.0001
Nontypeable 8 (1.6) 10 (2.5) 0.3357
Haemophilus influenzae – any serotype 139 (27.7) 524 (44.9) <0.0001 175 (43.8) <0.0001
Type a 2 (0.4) 4 (0.3) 0.8599
Type b 4 (0.8) 0 (0) 0.0022 – –
Type d 0 (0) 1 (0.1) 0.5122 – –
Type e 3 (0.6) 8 (0.7) 0.8410 – –
Type f 0 (0) 2 (0.2) 0.3538 – –
Nontypeable 130 (26.0) 509 (43.6) <0.0001 – –
a Missing values excluded from denominator.
b Comparing Phase 1 with Phase 2 overall.
c Comparing Phase 1 with Phase 2 subset tested for S. pneumoniae.
d Refers to children aged 0–10 years in addition to study participant.
e Excludes PCV10-related serotypes and nontypeable isolates.
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We observed a robust impact of PCV10 on NP carriage with vac-
cine serotypes within 3 years of vaccine introduction in Brazil. The
prevalence of vaccine-type carriage declined by >90%, and the
effectiveness of 3 or 4 doses was >92%. PCV10 also led to a reduc-
tion in carriage of penicillin-resistant strains, consistent with the
experience with 7-valent PCV [28]. As expected, there was an
increase in the prevalence of carriage with non-vaccine serotypes
[29]. We also found an increase in vaccine-related serotypes, lar-
gely driven by the emergence of serotype 6C as the most common
serotype in the post-PCV10 survey. Despite speculation that PCV10
might protect against colonization by NTHi, we observed a signifi-
cant increase in NTHi carriage following PCV10 introduction and a
significant association between PCV10 vaccination and carriage of
NTHi.The impact of PCV introduction on carriage of vaccine serotypes
is consistent with results on PCV7 in a variety of settings [13].
However data are more limited on PCV10. A study in Goiania,
Brazil conducted soon after PCV10 introduction compared the
prevalence of vaccine-type carriage among vaccinated and
non-vaccinated children and found the effectiveness of PCV10
(defined as 1-rate ratio ⁄ 100%) to be 35.9–44.0% [30]. A study con-
ducted by Hammitt et al. in Kilifi, Kenya found that within 2 years
of PCV10 introduction, carriage of vaccine serotypes among all
children <5 years had declined by 63% [31]. As with our study,
the study by Hammitt was conducted in a setting where a catch-
up campaign had been carried out among children <5 years, and
where coverage was reasonably high; coverage in Kilifi with at
least one dose among children <5 years was 79% in 2012. Because
most low- and middle-income countries introduce PCV with no (or
only limited) catch-up, and coverage in many settings is lower than
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Fig. 1. Serotype distribution among pneumococcal carriage isolates before (n = 207) and after (n = 198) PCV10 introduction.
Table 2
Factors associated with colonization with vaccine-type Streptococcus pneumoniae.
Colonized
n = 106
n (%)
Not colonized
n = 795
n (%)
Crude odds ratio
(95% CI)
P value Adjusted odds ratio
(95% CI)
PCV10 effectiveness
(95% CI)
Age < 18 months 45 (42.4) 439 (55.2) 0.598 (0.397, 0.901) 0.0140 –
Male sex 57 (53.8) 426 (53.6) 1.008 (0.671, 1.513) 0.9708 –
Attends day care 46 (43.4) 197 (24.8) 2.327 (1.535, 3.530) <0.0001 2.358 (1.455, 3.821)
Mother educational level 6 8th grade 41 (39.8) 223 (28.3) 1.675 (1.097, 2.560) 0.0170 –
Smoker in the household 38 (35.8) 225 (28.3) 1.413 (0.923, 2.164) 0.1113 –
Household income 6 1530 R per month 64 (71.1) 480 (66.8) 1.226 (0.757, 1.984) 0.4076 –
P2 people aged 0–10 years in household (in
addition to participant)
43 (40.6) 316 (39.8) 1.035 (0.685, 1.564) 0.8714 –
P3 people aged 11 years or older in household 48 (45.3) 311 (39.1) 1.288 (0.856, 1.937) 0.2242 –
P3 people sleep in same room as child 28 (26.4) 196 (24.8) 1.092 (0.688, 1.731) 0.7095 –
Region
North 53 (50.0) 287 (36.1) Ref
South 9 (8.5) 80 (10.1) 0.609 (0.288, 1.288) 0.1945 –
East 0 (0) 5 (0.6) – 0.9880 –
Central West 34 (32.1) 325 (40.9) 0.567 (0.358, 0.896) 0.0152 –
South East 10 (9.4) 98 (12.3) 0.553 (0.271, 1.128) 0.1033 –
Colonization with Haemophilus influenzae 53 (50.0) 261 (32.8) 2.046 (1.360, 3.078) 0.0006 2.454 1.529 3.939
PCV10 dosesa
0 99 (93.4) 402 (50.8) Ref Ref
1 0 (0) 6 (0.8) – 0.9866 –
2 1 (0.9) 21 (2.6) 0.193 (0.026, 1.455) 0.1105 0.122 (0.016, 0.951) 87.8 (4.9, 98.4)
3 4 (3.8) 168 (21.1) 0.097 (0.035, 0.267) <0.0001 0.073 (0.026, 0.204) 92.7 (79.6, 97.4)
4 2 (1.9) 198 (24.9) 0.041 (0.010, 0.168) <0.0001 0.027 (0.007, 0.113) 97.3 (88.7, 99.3)
a Reference is 0 doses.
5608 M.-C.C. Brandileone et al. / Vaccine 34 (2016) 5604–5611that of Kilifi or São Paulo, the impact of vaccine introduction on
vaccine-type carriage in other settings may not be as rapid.
We found no protection of PCV10 against carriage of vaccine-
related serotypes. Pre-licensure immunogenicity data suggested
that PCV10 might offer cross-protection against vaccine-related
serotypes 6A and 19A [16,32]. A study from Finland reported a sig-
nificant decline in invasive disease caused by both of these
vaccine-related serotypes following introduction of PCV10 as a
routine infant immunization [33]. A case-control study of PCV10
effectiveness against invasive pneumococcal disease carried outin 10 states of Brazil (including São Paulo) found the vaccine to
be significantly protective against vaccine-related serotype 19A
[15,32]. Despite such evidence of cross-protection against invasive
disease, in this study there was no evidence of PCV10 impact
against carriage of either serotype 6A or 19A. This finding is consis-
tent with the carriage study conducted in Kilifi [31], and an obser-
vational study from the Netherlands [34], where no effect of PCV10
was observed against vaccine-related serotypes. In contrast, a
recent trial from Finland reported a significant reduction in car-
riage of serotype 19A among children receiving a 4-dose (3 + 1)
Table 3
Factors associated with colonization with non-typeable Haemophilus influenzae.
Colonized
n = 639
n (%)
Not colonized
n = 1029
n (%)
Crude odds ratio
(95% CI)
P value Adjusted odds ratio
(95% CI)
PCV10 effectiveness
(95% CI)
Age < 18 months 339 (53.05) 581 (56.46) 0.871 (0.715, 1.062) 0.1734 –
Male sex 327 (51.17) 542 (52.67) 0.942 (0.773, 1.147) 0.5513 –
Attends day care 325 (50.86) 155 (15.06) 5.836 (4.634, 7.351) <0.0001 7.270 (5.619, 9.405)
Mother educational level 6 8th grade 181 (28.68) 279 (27.38) 1.067 (0.856, 1.331) 0.5644 –
Smoker in the household 195 (30.56) 260 (25.27) 1.302 (1.045, 1.621) 0.0184 1.357 (1.047, 1.759)
Household income 6 1530 R per month 463 (77.04) 652 (68.42) 1.549 (1.226, 1.957) 0.0002 1.733 (1.322, 2.271)
P2 people aged 0–10 years in household
(in addition to participant)
317 (49.61) 363 (36.1) 1.731 (1.417, 2.116) <0.0001 1.805 (1.425, 2.286)
P3 people aged 11 years or older in household 228 (35.68) 424 (41.21) 0.792 (0.646, 0.971) 0.0247 –
P3 people sleep in same room as child 188 (29.42) 252 (24.56) 1.280 (1.026, 1.598) 0.0289 –
Region
North 173 (27.07) 287 (27.89) Ref –
South 126 (19.72) 172 (16.72) 1.215 (0.903, 1.636) 0.1987 –
East 51 (7.98) 88 (8.55) 0.961 (0.649, 1.425) 0.8446 –
Central West 173 (27.07) 295 (28.67) 0.973 (0.746, 1.269) 0.8395 –
South East 116 (18.15) 187 (18.17) 1.029 (0.763, 1.387) 0.8508 –
PCV10 dosesa
0 130 (20.34) 371 (36.05) Ref Ref
1 5 (0.78) 3 (0.29) 4.756 (1.121, 20.181) 0.0344 5.400 (1.136, 25.678) 440 (2467.8, 13.6)
2 24 (3.76) 26 (2.53) 2.634 (1.461, 4.751) 0.0013 2.001 (1.010, 3.966) 100.1 (296.6, 1.0)
3 208 (32.55) 280 (27.21) 2.120 (1.621, 2.773) <0.0001 2.176 (1.586, 2.986) 117.6 (198.6, 58.6)
4 272 (42.57) 349 (33.92) 2.224 (1.724, 2.870) <0.0001 2.078 (1.536, 2.812) 107.8 (181.2, 53.6)
a Reference is 0 doses.
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dose (2 + 1) schedule [35]. Further study of the impact of PCV10 on
vaccine-related serotypes is needed. It is possible that protection
against carriage requires higher antibody levels than protection
against invasive disease. Because impact against carriage is so
important for developing indirect effects [14], it will be important
to monitor disease trends for serotypes 6A and 19A in countries
using PCV10.
Serotype 6C is also in the same serogroup as vaccine-type 6B,
yet we found a significant increase in the prevalence of 6C carriage
following PCV10 introduction. PCV7 does not provide cross protec-
tion against 6C [36,37], and increases in 6C carriage were observed
following PCV7 introduction [38]. Serotype 6C has been found to
be relatively non-invasive compared with other serotypes [39].
However given its emergence as the most common colonizing ser-
otype in the post-PCV10 phase, it will be important to monitor for
any increases in 6C invasive disease.
Despite speculation that PCV10 could lead to a decline in NTHi
pneumonia and otitis media mediated through a reduction in car-
riage [16], in our study NTHi carriage increased significantly post-
PCV10, and PCV10 vaccination was strongly associated with car-
riage even after adjusting for other risk factors. A clinical trial of
an 11-valent precursor to PCV10 carried out in the Czech Republic
and Slovakia demonstrated efficacy against otitis media caused by
NTHi [40] and against Hi colonization [41], although not statisti-
cally significant when molecular methods were used in addition
to standard microbiologic techniques. Subsequent clinical trials
of PCV10 in the Czech Republic [42], the Netherlands [43], Kenya
[44] and Finland [35] found no consistent impact on NTHi carriage.
Following PCV10 introduction in Kenya, a significant decline in
NTHi carriage was observed in Kilifi when comparing baseline
(2009–2010) to post-PCV10 years (2011–2012); however NTHi
carriage increased from 2011 to 2012, and vaccination with 2 or
more doses (compared with 0 or 1 dose) of PCV10 was not signif-
icantly protective against NTHi carriage [31]. Based on available
data it was not surprising that we found no protection against
NTHi carriage; however the reason for the observed increase in
NTHi carriage and significant association between PCV10 vaccina-
tion and NTHi carriage is unknown. Because baseline specimens
were collected predominantly in the month of March and post-PCV10 specimens in June, it is possible that seasonal differences
in NTHi carriage impacted the results. It is also possible that the
increase in NTHi may be related to the observed increase in overall
pneumococcal carriage, since carriage with one has been positively
associated with carriage of the other [45]. The relationship
between bacteria in the nasopharynx is complex [46], and it is
unclear whether an increase in NTHi might translate into an
increase in NTHi disease. Further study of the short- and long-
term impact of PCV10 on NTHi carriage is needed.
Beyond vaccination, we identified additional risk factors for Spn
and NTHi carriage. Attending day care was a risk factor common to
both; this finding is consistent with multiple studies in a variety of
settings [47–49]. Adequate vaccination is a requirement for enroll-
ment in day care centers in Brazil, although one study found that
10.9% of 18-month olds enrolled in day care in São Paulo were
incompletely vaccinated [50]. For NTHi, we also found that low
income, multiple children in the house in addition to the study par-
ticipant, and having a smoker in the household were risk factors for
carriage. These findings are consistent with known risk factors for
pneumonia [51], and highlight the importance of multifaceted
strategies for reducing the risk of respiratory disease in children.
Vaccination with PCV10 is an extremely important tool, but other
prevention efforts are needed, particularly to reduce NTHi disease.
This study had several limitations. Participants were a conve-
nience sample recruited from vaccine centers during campaigns,
and the study was conducted in a single city, both of which limit
generalizability. PCV10 had recently been introduced at the time
of the baseline survey; we excluded children who had received
PCV10, however it is possible that early indirect effects may have
affected the observed prevalence of vaccine-type carriage at base-
line. As noted above, the baseline specimens and post-PCV speci-
mens were not all collected at the same time of year; therefore
seasonal variations in carriage may have impacted the results.
Detection of Spn was done by culture, which is less sensitive than
PCR, so we may have failed to detect some pneumococcal carriage
or carriage with multiple serotypes. Certain vaccine serotypes,
such as 1 and 5, are uncommonly found in carriage despite being
important causes of disease [52] so carriage studies do not provide
data on PCV10 impact against those serotypes. Furthermore, sero-
types 4, 7F and 9V were either rare or absent in this setting, so our
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driven only five serotypes (6B, 14, 18C, 19F and 23F). Finally, other
non-vaccine factors can influence carriage prevalence over time;
we attempted to adjust for potential confounders in our calcula-
tions of vaccine effectiveness, however there may be other factors
which we did not account for.
Despite these limitations, we show a clear impact of PCV10 on
carriage of vaccine serotypes within 3 years after vaccine introduc-
tion. These data add to the growing evidence base of PCV10 impact
and effectiveness in Brazil [30,53–55] and elsewhere [31,33,56,57],
and can help guide policy decisions. We showed no protection
against carriage of vaccine-related serotypes, and increases in NTHi
warrant further monitoring. Yet our findings support the use of
PCV10 to reduce the burden of pneumococcal disease in Brazil
and globally.
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